CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Columnist Shalom Lim shares how his business, Rebirth Ensemble, will allow him to pursue visual arts and support artists with disabilities.

Zinc supplementation showed limited benefits in improving muscle health and hydration in boys with DMD. Nearly 30% of participants had low zinc levels initially, with slight improvement post ...

Cardiac complications like arrhythmias, heart failure, and myocardial infarction significantly impact mortality rates in patients with comorbidities. The interaction between cardiac issues and ...

The Committee for Medicinal Products for Human Use (CHMP) — part of the European Medicines Agency — again maintained its recommendation not to renew conditional marketing authorization for Translarna ...

Apart from the AATD indication, there are several other candidates like WVE-N531, WVE-003 and WVE-007 in Wave Life Sciences’ pipeline, which are being developed for rare and prevalent diseases ...

Wave is now looking for new partners for this program. Wave also announced good phase 2 results for its Duchenne muscular dystrophy candidate WVE-N531 earlier this year and is developing therapies for ...

The biotechnology company reported promising data from its Duchenne muscular dystrophy (DMD) drug candidate, WVE-N531, which led to raised share targets by B.Riley and JPMorgan. Analysts from B ...